Uterine Neoplasms, Version 1.2023

Adenocarcinoma of the endometrium (also known as endometrial can-cer, or more broadly as uterine cancer or carcinoma of the uterine cor-pus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcino-mas with high-risk endometrial histology (including uterine serous carci-noma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Mu euro llerian tumor], and undifferentiated/dedifferentiated carci-noma). Stromal or mesenchymal sarcomas are uncommon subtypes ac-counting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The com-plete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org.J Natl Compr Canc Netw 2023;21(2):181-209doi: 10.6004/jnccn.2023.0006

Automated summary

Adenocarcinoma of the endometrium is the most common malignancy of the female genital tract in the United States, with an estimated 65,950 new cases in 2022 and 12,550 deaths. It includes pure endometrioid cancer and carcinomas with high-risk endometrial histology. Stromal or mesenchymal sarcomas are rare subtypes accounting for approximately 3% of all uterine cancers. This article focuses on the diagnosis, staging, and management of pure endometrioid carcinoma from the NCCN Guidelines for Uterine Neoplasms.